Key Highlights

  • Shares moved roughly 14.5% higher, extending a recovery off multi-year lows
  • Record first-half Revenue reached $8.3 million, up 72% on the first half of 2025
  • Full-year 2026 revenue guidance was raised to no less than $14.8 million, from around $13.3 million previously
  • The company funded 2025's 61% revenue growth without raising fresh shares
  • Three customers accounted for 48% of 2025 revenue, up from 40% a year earlier

The AIM-listed maker of plant-derived polymers has posted its fastest revenue growth on record and lifted full-year guidance, prompting a sharp re-rating in a stock that had long traded well below the radar.

A neglected small-cap catches a bid

Itaconix (LSE:ITX) is not the sort of company that usually draws crowds. A specialty-chemicals micro-cap that makes bio-based polymers from plant-derived itaconic acid, it sits at the smaller end of London's junior market, trades thinly, and spent years as a promising-but-loss-making science story. So a double-digit jump in the shares stands out. The stock has moved roughly 14.5% higher, extending a recovery that has taken it well off its lows and briefly putting a company most investors have never heard of onto the screens of those who hunt turnaround stories.

The proximate backdrop is a materially improved trading picture rather than any single fresh announcement on the day. In a market this illiquid, a modest amount of buying can push the price sharply, and moves of this size can occur without a same-day regulatory release. What has clearly changed over recent months is the fundamental trajectory: Itaconix is now growing quickly, guiding ahead of prior expectations, and edging towards the profitability that has eluded it since it listed.

Record first half and a raised outlook

The pivotal development came when Itaconix issued a trading update reporting record first-half revenue of $8.3 million, up 72% on the $4.8 million booked in the first half of 2025 and 46% higher than the $5.7 million recorded in the second half of last year. Growth was described as broad-based, driven by strong reorder volumes from existing customers alongside new unit-dose detergent wins — a dish detergent customer in EMEA and a laundry detergent customer in North America — plus rising uptake of the company's SPARX formulated solutions.

Crucially, management used the update to raise guidance. Itaconix now expects full-year 2026 revenue of no less than $14.8 million, comfortably ahead of the roughly $13.3 million the market had previously been working towards, and still anticipates delivering a small positive EBITDA for the year even as it continues to invest. Gross Margin was guided to around 36% for the first half, broadly in line with 2025, which suggests the top-line surge is not being bought through heavy discounting. Interim results are expected in September, letting investors verify the headline figures and, importantly, see an updated cash position.

The financial and operational picture

Context from the March 2026 full-year results explains why the market had grown more constructive. For 2025, Itaconix reported revenue of $10.5 million, a 61% increase on the prior year, with gross margin held at 35% — and 41% in the core Performance Ingredients business. The operating loss before exceptional items narrowed to about $1.04 million and the net loss improved to $1.38 million from $2.02 million in 2024. The company ended the year with $2.4 million of cash plus a further $2.0 million held in investments, giving roughly $4.4 million of total liquidity, and notably it funded 2025's growth without raising fresh shares.

Operationally, the Business is built around three strands: Performance Ingredients, the established polymers sold into cleaning, hygiene and beauty formulations; SPARX formulated solutions, which package that chemistry for solid and unit-dose formats; and earlier-stage platforms including BIO*Asterix and BioVail aimed at longer-dated opportunities in areas such as paints and crop production. The Investment case rests on the idea that consumer-goods brands increasingly need bio-based, biodegradable ingredients to replace legacy petrochemical polymers, and that Itaconix's patented chemistry gives it a defensible niche.

The arithmetic is improving but the company remains small and, on trailing figures, loss-making. With a modest cash buffer and an ambition to keep investing in capacity and products, the path to sustained cash generation depends on current revenue momentum being maintained rather than proving a one-off.

What could drive the shares next?

The nearest catalyst is the interim results due in September, which will confirm the first-half numbers and, for the first time since the March accounts, reveal how the Balance Sheet has moved through a period of rapid growth and working-capital demands. A clean set of figures showing the guided margin and a credible route to positive EBITDA could reinforce the re-rating; any sign that faster sales are consuming cash would temper it.

Beyond that, further wins in unit-dose detergents — the format doing much of the heavy lifting so far — would show that Demand is broadening rather than concentrating. Progress on the earlier-stage BIO*Asterix and BioVail platforms, or traction in adjacent markets such as coatings and agriculture, would give investors reason to underwrite a longer growth runway. And because the shares are so thinly traded, even incremental institutional interest could have an outsized effect on the price.

Risks investors should watch

Customer concentration is the most obvious vulnerability. The 2025 accounts showed three customers accounting for 48% of revenue, up from 40% a year earlier, so the loss or de-stocking of a single large account could knock a meaningful hole in the top line. Rapid growth of this kind can also mask lumpiness: reorder patterns in detergents can swing between halves, and the 46% sequential jump sets a demanding comparison base.

Funding is the other watch item. With roughly $4.4 million of total Liquidity at the last count and a business still consuming cash while it invests, any stumble in the growth trajectory could revive the question of whether Itaconix needs to return to the market for fresh Capital — a real dilution risk at this size. Raw-material costs and the pace at which large brands actually reformulate towards bio-based ingredients are outside the company's control. And the same thin liquidity that amplifies rallies works in reverse, so sharp pullbacks are equally possible on little news.

Investor takeaway

The recent share-price strength looks less like a random spike and more like the market catching up with a genuinely improved fundamental story: 72% first-half growth, guidance raised to at least $14.8 million, stable margins and a company inching towards profitability without, so far, having to dilute shareholders. That is a meaningful shift for a business that spent years as a speculative science play.

It is worth keeping perspective, though. Itaconix (LSE:ITX) remains a micro-cap with concentrated customers, a slim cash cushion and a share register thin enough to exaggerate moves in both directions. The September interims are the next real test — of the numbers, of the margin, and above all of the cash position. Investors will be watching whether the rediscovery of this small-cap story is the start of a durable re-rating or simply a burst of enthusiasm that the fundamentals will have to grow into.